SIGA TECHNOLOGIES INC Q1 FY2026 earnings call

• SIGA's focus is partnering with global governments to build bio-threat preparedness strategies, particularly for smallpox, with TPOX positioned for rapid deployment. • First quarter had minimal product deliveries, second quarter expects deliveries. • Maintains engagement with U.S. government, secured funding in 2025 for pediatric and IV efforts. • International business has $13M order in Asia Pacific to be delivered in Q2 and exclusive license/distribution agreement with HICMA for MENA region. • Advancing pediatric PEP program with IND filed and Phase I study initiated, targeting FDA submission for PEP indication in next 12 months.

The first quarter of 2026 had minimal product deliveries. Product revenues for the quarter included approximately $1 million of IV TPOCs deliveries to the S&S and approximately $2 million of reimbursement revenues in connection with the manufacturing technology transfer. There were also research and development revenues of approximately $3 million. Pre-tax operating loss for the quarter was approximately $5 million, and net loss was approximately $3 million. Fully diluted loss per share for the three months ended March 31st, 2026 was 5 cents. As of March 31st, 2026, the company had a cash balance of approximately $146 million and no debt. The second quarter is expected to deliver approximately 13 million of oral TPOCs to an international customer and additional IV TPOCs deliveries to SNS.

• First quarter had variable business rhythm; second quarter expects specific product deliveries. • Long-term outlook offers substantial opportunities based on business fundamentals and need for bio-threat protection. • Pace of U.S. government contract progress slower but funding secured in 2025 signals TPOX's role in U.S. preparedness.

• Business has quarter-to-quarter variability, so results should be viewed in longer-term context. • Geopolitical tension, accelerating tech risks (including AI), and growing biological threats pose risks to investment and business.

Q: Related to CHMP's recent recommendation on TPoC for MPoC treatment, impact on broader labeling in Europe?

A: CHMP reaffirmed positive benefit-risk balance for smallpox, cowpox, and vaccinia complications, currently taking steps to implement CHMP recommendation on withdrawing MPOX indication.

Q: Comfort with dividend payout given lumpy revenues?

A: Dividend declared with understanding of business variability, cash balance still over $100M after payout, well-positioned for near-term gaps.

Q: Key priorities for capital deployment, acquisitions/in-licensing?

A: Actively exploring ways to expand pipeline through acquisition or in-licensing to deploy capital for greatest value.

Q: Broader increase in stockpiling interest across international markets and HICMA deal economics?

A: Engaged with other potential customers, HICMA can unlock demand in MENA region, supply finished product to HICMA who manages customer relationships, financial terms confidential.